Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urinary Biomarker Study of Sulindac and DFMO
NCT01636128Phase 2Withdrawn
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) and Colorectal Adenoma (CRA) comparing Sulindac first with DFMO first (2 arms). Primary endpoints: Intra-subject urine N1-monoacetylspermidine variability, Intra-subject urine dcSAM variability and 4 more. Planned start Mar 2014; status: withdrawn.
02
Drugs
eflornithinesulindac
03
Conditions
colorectal cancer (CRC)Colorectal Adenoma (CRA)
Beyond the preview
Go deeper on NCT01636128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636128.